CD-10 activated prodrug compounds

Details CD-10 activated prodrug compounds CD-10 activated prodrug compounds

2007-12-04

2007-12-04

Russel, Jeffrey Edwin (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S017400, C514S018700, C530S329000, C530S330000, C530S331000, C530S345000

Reexamination Certificate

active

11022341

ABSTRACT:
The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing a prodrug are also disclosed.

REFERENCES:
patent: 4703107 (1987-10-01), Monsigny et al.
patent: 5599686 (1997-02-01), DeFeo-Jones et al.
patent: 5962216 (1999-10-01), Trouet et al.
patent: 6844318 (2005-01-01), Copeland et al.
patent: 2002/0103133 (2002-08-01), Copeland et al.
patent: WO-96/05863 (1996-02-01), None
patent: WO-98/52966 (1998-11-01), None
patent: WO 00/33888 (2000-06-01), None
patent: WO-00/69472 (2000-11-01), None
patent: WO-01/68145 (2001-09-01), None
patent: WO-01/95943 (2001-12-01), None
patent: WO-01/95945 (2001-12-01), None
patent: WO-02/00263 (2002-01-01), None
Albright et al. Matrix metalloproteinase-activated doxorubicin prodrugs . . . Molecular Cancer Therapeutics. May 2005, vol. 4, No. 5, pp. 751-760.
Trouet et al. Extracellularly Tumor-activated Prodrugs for the Selective Chemotherapy of Cancer . . . Cancer Research. Apr. 1, 2001. vol. 61, pp. 2843-2846.
Baraniuk, J.N. et al., “Identification of neural endopeptidase mRNA in human nasal mucosa,”J. appl. Physiol., vol. 74(1):272-276 (1993).
Barker, P.E. et al., “The common acute lymphoblastic leukemia antigen gene maps to chromosomal region 3 (q21-q27),”J. Immunol., vol. 142(1):283-287 (1989).
Bateman, R.C., Jr. et al., “Identification of the active-site arginine in rat neutral endopeptidase 24.11 (enkephalinase) as arginine 102 adn analysis of a glutamine 102 mutant,”J. Biol. Chem., vol. 264(11):6151-6157 (1989).
Bricout, H. et al., “Synthetic and Kinetic Aspects of Nickel-Catalysed Amination of Allylic Alcohol Derivatives,”Tet. Lett., vol. 54:1073-1084 (1998).
Casey, M.L. et al., “Progesterone-regulated cyclic modulation of membrane metalloendopeptidase (enkephalinase) in human endometrium,”J. Biol. Chem., vol. 266(3):23041-23047 (1991).
Casimir Jr., et al., “First Application of the Dakin-West Reaction to Fmac Chemistry: Synthesis of the ketomethylene tripeptide Fmox-Nα-Asp(tBu)-(R,S)Tyr(tBu)ψ(CO—Ch2)Gly—OH,”Tet. Lett., vol. 36(27):4797-4800 (1995).
Chaires, J.B. et al., “Self-association of daunomycin,”Biochemistry, vol. 21(17):3927-3932 (1982).
Chu, P. et al., “Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma,”Am. J. Clin. Pathol., vol. 113(3):374-382 (2000).
Connelly, J.C. et al., “Neutral endopeptidase 24.11 in human neutrophils: cleavage of chemotactic peptide,”Proc. Natl. Acad. Sci. USA, vol. 82(4):8737-8741 (1985).
Devault, A. et al., “Amino acid sequence of rabbit kidney neutral endopeptidase 24.11 (enkephalinase) deduced from a complementary DNA,”EMBO J., vol. 6(5):1317-1322 (1987).
GenBank Accession No. Y00811, Jongeneel, C.V., “Common acute lymphocatic leukemia is identical to neutral endopeptidase,”J. Exp. Med., Sep. 12, 1993.
Genet, J.P. et al., “Practical Palladium-Mediated Deprotective Method of Allyloxycarbonyl in Aqueous Media,”Tetrahedron, vol. 50(2):497-503 (1994).
Genet, J.P. et al., “A General and Simple Removal of the Allyloxycarbonyl Protecting Group by Palladium-Catalyzed Reactions Using Nitrogen and Sulfur Necleophiles,”Synlett., pp. 680-682 (1993).
Greaves, M.F. et al., “Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts,”Blood, vol. 61(4):628-639 (1983).
Hayakawa, E. et al., “Viscosity Study on the Self-Association of Doxorubicin in Aqueous Solution,”Chem. Pharm. Bull., vol. 39:1282-1286 (1991).
Head Jr. et al., “Cellular localization of membrane metaloendopeptidase (enkephalinase) in human endometrium during the ovarian cycle,”J. Clin. Endocrinol. Metab., vol. 76(3):769-776 (1993).
Hersh, L.B. et al., “Comparison of the subsite specificity of the mammalian neutral endopeptidase 24.11 (enkephalinase) to the bacterial neutral endopeptidase thermolysin,”J. Biol. Chem., vol. 261(14):6433-6437 (1986).
Indig, F.E. et al., “Investigation of neural endopeptidases (EC 3.4.24.11) and of neutral proteinases (EC 3.4.24.4) using a new sensitive two-stage enzymatic reaction,”FEBS Lett., vol. 255(2):237-240 (1989).
Kenny, A.J. et al., “Cell surface peptidases,”Mammalian Ectoenxymes, Kenny, A.J. (eds.) pp. 169-210, Elsevier, Amsterdam, New York, Oxford (1987).
Kenny, A.J., “Cell surface peptidases are neither peptide- nor organ-specific,”Trends Biochem. Sci., vol. 11:40-42 (1986).
Krongrad, A. et al., “Endopeptidase 24.11 activity in the human prostate cancer cell lines LNCaP and PPC-1,”Urol. Res., vol. 25(2):113-116 (1997).
Letarte, M. et al., “Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase,”J. Exp. Med., vol. 168(4):1247-1253 (1988).
Li, C. et al., “Neprilysin: assay methods, purification, and characterization,”Methods Enzymol., vol. 248:253-263 (1995).
Liu, A. Y. et al., “Differential expression of cell surface molecules in prostate cancer cells,”Cancer Res., vol. 60(13):3429-3434 (2000).
Malfroy, B. et al., “High-affinity enkephalin-degrading peptidase in brain is increased after morphine,”Nature, vol. 276(5687):523-526 (1978).
Matsas, R. et al., “The metabolism of neuropeptides. The hydrolysis of peptides, including enkephalins, tachykinins and their analogues, by endopeptidase-24.11,”Biochem. J., vol. 223(2):433-440 (1984).
Matzanke, B.F. et al., “Evidence for polynuclear aggregates of ferric daunomycin. A Mossbauer, EPR, X-ray absorption spectroscopy and magnetic susceptibility study,”Eur. J. Biochem., vol. 207(2):747-755 (1992).
Pozsgay, M. et al., “Substrate and inhibitor studies of thermolysin-like neutral metaloendopeptidase from kidney membrane fractions. Comparison with bacterial thermolycin,”Biochemistry, vol. 25(6):1292-1299 (1986).
Sales, N. et al., “Neutral endopeptidase 24.11 in rat peripheral tissues: comparative localization by ‘ex vivo’ and ‘in vitro’ autoradiography,”Regul. Pept., vol. 33:209-222 (1991).
Schmittberger, T. et al., “Synthesis of the Palmitoylated and Prenylated C-terminal Lipopeptides of the Human R- and N-RasProteins,”Bioorg. Med. Chem., vol. 7:749-762 (1999).
Shapiro, G. et al., “Mild and Rapid Azide-Mediated, Palladium Catalyzed Cleavage of Allylester Based Protecting Groups,”Tet. Lett., vol. 35(30):5421-5424 (1994).
Suzuki, T. et al., “Imbalance between neutral endopeptidase 24.11 and endothelin-1 expression in human endometrial carcinoma,”Oncology, vol. 60(3):258-267 (2001).
Tabrizi-Fard et al., “Evaluation of the Pharmacokinetic Properties of a Doxorubicin Prodrug in Female ICR (CDI Mice) following intravenous administration,”Proc. American Association for Cancer Research, vol. 42:324, No. 1746 (2001).
Turner, A.J., “Neprilysin,”Handbook of Proteolytic Enzymes, Barrett, A.J. et al., (eds.), Chapt. 362, pp. 1080-1085, Academic Press (1998).
van der Vijgh, W.J. et al., “Comparative metabolism and pharmacokinetics of doxorubicin and 4′-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice,”Cancer Chemother. Pharmacol., vol. 26(1):9-12 (1990).
Waksman, G. et al., “Binding of the bidentate inhibitor [3H]HACBO-Gly to the rat brain neutral endopeptidase ‘enkephalinase’, ”Biochem. Biophys. Res. Commun., vol. 131(1):262-268 (1985).
Weiss, L.M. et al., “Lymphoblastic lymphoma: an immunophenotype study of 26 cases with comparison to T

Affiliated with

Also associated with

Rating

CD-10 activated prodrug compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CD-10 activated prodrug compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD-10 activated prodrug compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3872183